Research Analysts Issue Forecasts for SNDX FY2025 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – B. Riley lifted their FY2025 EPS estimates for Syndax Pharmaceuticals in a research report issued on Tuesday, November 4th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($2.98) per share for the year, up from their previous forecast of ($3.28). B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals’ Q4 2025 earnings at ($0.46) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at $1.04 EPS and FY2028 earnings at $1.89 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.04. The business had revenue of $45.87 million for the quarter, compared to analyst estimates of $49.08 million. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The business’s quarterly revenue was up 266.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.98) EPS.

SNDX has been the subject of a number of other reports. UBS Group raised their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group raised their target price on Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a report on Friday, September 5th. BTIG Research restated a “buy” rating and set a $56.00 target price on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. Citigroup boosted their price objective on Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.70.

Syndax Pharmaceuticals Stock Down 1.6%

NASDAQ SNDX opened at $15.10 on Thursday. The business has a fifty day moving average price of $15.30 and a 200 day moving average price of $12.63. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $22.50. The company has a debt-to-equity ratio of 2.06, a quick ratio of 4.55 and a current ratio of 4.71. The company has a market cap of $1.30 billion, a P/E ratio of -3.88 and a beta of 0.73.

Institutional Trading of Syndax Pharmaceuticals

Large investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in Syndax Pharmaceuticals in the first quarter valued at $25,000. Lazard Asset Management LLC acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at $66,000. Tower Research Capital LLC TRC grew its holdings in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after purchasing an additional 4,308 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at $97,000. Finally, Raymond James Financial Inc. acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at $103,000.

Insiders Place Their Bets

In related news, CEO Michael A. Metzger sold 157,307 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the transaction, the chief executive officer owned 298,661 shares of the company’s stock, valued at $4,901,027.01. This represents a 34.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Dennis Podlesak sold 19,200 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $15.84, for a total value of $304,128.00. Following the transaction, the director directly owned 191,763 shares in the company, valued at $3,037,525.92. This represents a 9.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 195,707 shares of company stock worth $3,183,904 in the last ninety days. 4.10% of the stock is currently owned by corporate insiders.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).